Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma.
Cancers (Basel). 2021 Feb 24;13(5):944. doi: 10.3390/cancers13050944.
Cancers (Basel). 2021.
PMID: 33668183